Adalimumab Injection ( DrugBank: Adalimumab )

3 diseases

40. 高安動脈炎

臨床試験数 : 24 / 薬物数 : 40 - (DrugBank : 18) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05151848 (ClinicalTrials.gov)	January 5, 2022	6/11/2021	Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis	An Open-label,Randomized, Controlled, Multicenter Study of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis	Takayasu Arteritis	Drug: Adalimumab Injection;Drug: Tofacitinib 5 MG	Chinese SLE Treatment And Research Group	NULL	Recruiting	18 Years	65 Years	All	100	Phase 4	China

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05626348 (ClinicalTrials.gov)	December 22, 2021	15/11/2022	The Clinical Efficacy of Immunomodulators in RA Patients	The Clinical Study to Observe the Efficacy and Safety of Immunomodulators in Rheumatoid Arthritis Patients for 6 Months Treatment in China	Arthritis, Rheumatoid	Drug: Iguratimod;Drug: Methotrexate;Drug: Adalimumab Injection;Drug: Leflunomide;Drug: Hydroxychloroquine	Qilu Hospital of Shandong University	NULL	Recruiting	18 Years	80 Years	All	400	Phase 4	China
2	NCT04255134 (ClinicalTrials.gov)	September 7, 2020	14/11/2019	Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)	Comparison of Abatacept With Tumor Necrosis Factor Inhibitors in the Treatment of Rheumatoid Arthritis Pain: A Phase IV Trial	Rheumatoid Arthritis	Drug: Abatacept Injection;Drug: Adalimumab Injection	St George's, University of London	NULL	Recruiting	18 Years	75 Years	All	60	Phase 4	United Kingdom

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03220841 (ClinicalTrials.gov)	October 9, 2017	6/7/2017	Stricture Definition and Treatment (STRIDENT) Drug Therapy Study	Stricture Definition and Treatment (STRIDENT) Drug Therapy Study	Crohn Disease;Inflammatory Bowel Diseases;Stricture; Bowel	Drug: Adalimumab Injection;Drug: Thiopurine;Procedure: Endoscopic balloon dilatation	St Vincent's Hospital Melbourne	Australasian Gastro Intestinal Research Foundation;AbbVie	Active, not recruiting	18 Years	N/A	All	78	Phase 4	Australia
2	EUCTR2016-003321-42-NL (EUCTR)	18/01/2017	08/12/2016	Stepwise extention of the adalimumab injection interval in patients with stable Crohn's disease.	Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients: the LADI study.	Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Humira (adalimumab) Product Name: Adalimumab INN or Proposed INN: ADALIMUMAB	Radboud University Medical Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 4	Netherlands